Virios Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
VIRI Nasdaq 8731 https://www.virios.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Virios Therapeutics Inc

Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement - May 25th, 2023 8:05 pm
VIRI: Ready to Move IMC-1 Into Phase 3 Program… - May 16th, 2023 2:26 pm
Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia - May 15th, 2023 11:05 am
VIRI Stock Earnings: Virios Beats EPS Estimates - May 11th, 2023 11:49 am
We're A Little Worried About Virios Therapeutics' (NASDAQ:VIRI) Cash Burn Rate - May 11th, 2023 11:39 am
Virios Therapeutics Announces First Quarter 2023 Financial Results - May 11th, 2023 11:05 am
Virios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023 - May 4th, 2023 11:05 am
Virios Therapeutics Shares Almost Double In Trading Session - Here's Why - Apr 25th, 2023 5:07 pm
Virios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of Fibromyalgia - Apr 24th, 2023 8:15 pm
VIRI: Anticipating Update on IMC-1 Following ‘End-of-Phase 2’ Meeting with FDA… - Mar 16th, 2023 11:10 am
Virios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial Results - Mar 14th, 2023 11:05 am
Virios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023 - Mar 7th, 2023 12:05 pm
Virios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023 - Feb 13th, 2023 12:05 pm
Virios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 Program - Jan 5th, 2023 12:00 pm
Stock Pitch World Cup(TM), Educational Panels and 49 Companies to Present at the Planet MicroCap Showcase: VIRTUAL on December 6-8, 2022 - Dec 5th, 2022 1:30 pm
Virios Therapeutics, Inc. to Present at the Virtual Planet MicroCap Showcase - Nov 29th, 2022 12:05 pm
VIRI: Ready to Approach FDA with Phase 3 Plans… - Nov 22nd, 2022 11:15 am
Virios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate Update - Nov 14th, 2022 12:05 pm
Virios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022 - Nov 3rd, 2022 11:05 am
VIRI: Raises Gross Proceeds of $5 Million Through Underwritten Public Offering… - Sep 23rd, 2022 11:27 am